Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 5,232 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Infection Clear all

Conditions: Hepatitis C Infection
Interventions: Placebo, SCY-635, Pegasys, Copegus; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: San Francisco, California • Durham, North Carolina • San Antonio, Texas

Conditions: HIV Infections, Pregnancy
Interventions: Indinavir sulfate, Lamivudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 4
States / cities: San Francisco, California • Boston, Massachusetts • The Bronx, New York

Conditions: Respiratory Tract Infection
Interventions: RSV vaccine, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 1,153 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 145
States / cities: Birmingham, Alabama • Cullman, Alabama • Glendale, Arizona + 62 more

Conditions: Chlamydia Trachomatis Infection
Interventions: Rifalazil 25 milligram, Azithromycin 1 gram; Drug
Lead sponsor: ActivBiotics Pharma, LLC; Industry
Eligibility: 19 Years and older · Female only
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Birmingham, Alabama • San Diego, California • Indianapolis, Indiana + 2 more

Conditions: Opioid-Related Disorders, Opioid-use Disorder, Drug Addiction, Substance Use Disorders
Interventions: self-administered, e-health application; Other
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hospitalization, Infection
Interventions: Chlorhexidine gluconate (CHG), Iodophor (10% povidone-iodine); Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 13,952 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 28
States / cities: Anaheim, California • Bellflower, California • Capistrano Beach, California + 9 more

Conditions: Hepatitis C
Interventions: VCH-222 or matching placebo, peginterferon alfa-2a, ribavirin; Drug · Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 4
States / cities: Marietta, Georgia • Detroit, Michigan • Dallas, Texas + 1 more

Conditions: Hepatitis C, Chronic, Substance Use Disorders
Interventions: Peer specialist (PS), Incentives, telehealth visits, phone access; Behavioral
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: HIV, Heart Failure
Interventions: Exercise Intervention, Tailored Education sessions, Behavioral coaching, Mobile health support, General education; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 40 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Clostridium Difficile Colitis
Interventions: Ileal diversion and lavage, total abdominal colectomy; Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Asthma, Allergic Rhinitis
Interventions: Rhinovirus (GMP RV16 HRV-16); Biological
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 40 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Hydroxyurea, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Lamivudine, Stavudine, Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 63
States / cities: Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 37 more

Conditions: Covid19
Interventions: Smartphone-based voice and self-reported symptom collection; Other
Lead sponsor: Sonde Health; Industry
Eligibility: 12 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: San Diego, California • Boston, Massachusetts • New York, New York

Conditions: CMV Infection, Persistent CMV Viremia
Interventions: CMVpp65 Specific T-cells; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Surgical Wound, Wound Heal, Amputation
Interventions: PrevenaTM Device, Standard Dry Dressing; Device · Other
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: HIV, HIV Infections
Interventions: Stribild, ATV, Ritonavir, FTC/TDF, Stribild Placebo, ATV Placebo, RTV Placebo, FTC/TDF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 708 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 86
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 57 more

Conditions: Chronic Hepatitis C Virus
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 441 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 53
States / cities: Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 50 more

Conditions: HIV-1
Interventions: OZ1 transduced cells; Genetic
Lead sponsor: Janssen-Cilag Pty Ltd; Industry
Eligibility: Not listed
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2017
U.S. locations: 3
States / cities: Los Angeles, California • San Francisco, California • New York, New York

Conditions: HIV-1-infection
Interventions: PENNVAX-GP, INO-6145, INO-9012, CELLECTRA® 2000; Biological · Device
Lead sponsor: Steven Deeks; Other
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Los Angeles, California • San Francisco, California

Conditions: Urinary Tract Infections
Interventions: Uqora, Group1, Group 2; Dietary Supplement
Lead sponsor: Hawthorne Effect Inc.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Diego, California

Conditions: Respiratory Failure, ARDS
Interventions: Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol); Device
Lead sponsor: Marker Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 7
States / cities: Little Rock, Arkansas • Albuquerque, New Mexico • Portland, Oregon + 4 more

Conditions: Cataract
Interventions: Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: HIV Infection
Interventions: Efavirenz; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 3 Years to 16 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 27
States / cities: Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 19 more

Conditions: Carotid Artery Diseases, Aortic Diseases, Peripheral Arterial Diseases
Interventions: Intergard Standard - Collagen Coated Vascular Grafts and Patches, Hemashield - Collagen Coated Vascular Grafts and Patches, Intergard Silver - Antimicrobial Collagen Coated Vascular Grafts and Patches, Intergard Synergy - Antimicrobial Collagen Coated Vascular Grafts; Device
Lead sponsor: Intervascular; Industry
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Hershey, Pennsylvania • Pittsburgh, Pennsylvania

Search by objective public record fields.

Study of SCY-635, Pegasys and Copegus in Hepatitis C

A Study to Evaluate the Safety and Tolerance of Combination Anti-HIV Drug Therapy (Indinavir, Lamivudine, and Zidovudine) in HIV-Positive Pregnant Women and Their Infants

A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN

Safety and Efficacy Study of Rifalazil for the Treatment of Chlamydia Trachomatis Infection in Women

RETAIN: Retaining Opioid Users Entering Medication Assisted Treatment and Encouraging HCV/HIV Testing

Project PROTECT: Protecting Nursing Homes From Infections and Hospitalization

Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection

Linkage to Care for Persons With Hep C Infection

Proof-of-concept of a Behavioral Intervention to Improve the Cardiovascular Health of People Living With HIV

Optimal Surgical Treatment Of Fulminant Clostridium Difficile Colitis

Clinical Response to Rhinovirus Challenge

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

Improving Real-time COVID-19 Monitoring Through Smartphone Voice Analysis

Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

Evaluating the Outcomes for Incisional Application of Negative Pressure for Nontraumatic Amputations

Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection

Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical Trial

Therapeutic Vaccination in Treated HIV Disease

Uqora Supplements in Women With UTIs

Plasma Adsorption in Patients With Confirmed COVID-19

Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery

An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection

Intervascular Post-Market Clinical Follow-Up (PMCF) Registry